This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Editas (EDIT) Moves Ahead With its Portfolio Reprioritization
by Zacks Equity Research
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
by Zacks Equity Research
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Is Biogen (BIIB) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 70.9% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Predict a 107% Upside in Vir Biotechnology, Inc. (VIR): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 107.4% in Vir Biotechnology, Inc. (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 31.94% and 15.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
by Zacks Equity Research
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
by Zacks Equity Research
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.